Phase 3 N=151 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=244 A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Asthma
Primary: Maximum Observed Plasma Concentration (Cmax) of Mepolizumab — 11.57; 11.98; 12.07 micrograms per milliliter (µg/mL)
Phase 3 N=128 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Treatment Difference in Coefficient of Fat Absorption (CFA) Change From Baseline — -11.852 percent change from baseline
Phase 3 N=384 BOTOX® Treatment in Pediatric Lower Limb Spasticity
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6 — -1.06; -1.01; -0.80 score on a scale — p=0.010
Phase 3 N=698 Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study Drug — 81.4; 84.2 percentage of participants
Phase 3 N=321 Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Male Hypogonadism
Primary: Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dL — 83.6; 79.2 percentage of partipants
Phase 3 N=405 ProQuad® Intramuscular vs Subcutaneous
Measles · Mumps · Rubella
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment — 100; 100; 99.3; 99.3 Percentage of participants
Phase 3 N=227 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Psoriasis · Plaque Psoriasis
Primary: Proportion of Participants Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16 — 11.6; 81.4; 82.6 percentage of participants — p=<0.0001
Phase 3 N=495 Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Head and Neck Squamous Cell Cancer
Primary: Initial Overall Survival (OS) for All Participants — 8.4; 7.1 Months — p=0.03160
Phase 3 N=234 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
Psoriasis · Plaque Psoriasis
Primary: Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16 — 6.5; 66.5; 75.8 percentage of participants — p=<0.0001
Phase 3 N=204 Lubiprostone for the Treatment of Chronic Idiopathic Constipation
Constipation
Primary: Spontaneous Bowel Movement (SBM) Frequency at Week 1 — 3.6; 5.0 SBMs/week — p=0.003
Phase 3 N=1,025 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Change From Baseline in HbA1c 26 Weeks After Randomisation — -0.12; 0.005; -0.09 percentage of HbA1c — p=<0.001
Phase 3 N=1,463 Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX — 2130 TEAEs
Phase 3 N=29 Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Primary: Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab — 12; 8; 8; 4 Participants
Phase 3 N=251 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Turner Syndrome · Renal Insufficiency, Chronic · Pituitary Diseases
Primary: Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples — 223.54; 212.97; 238.02; 226.90 nanograms/milliliter (ng/mL)